66
Participants
Start Date
July 6, 2022
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2025
Nivolumab
Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
Ipilimumab
Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
Hospital Universitario Juan Ramón Jiménez, Huelva
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Central de Asturias, Oviedo
Complejo asistencial universitario de Salamanca, Salamanca
Hospital Universitario Virgen de la Macarena, Seville
Hospital Universitario de Toledo, Toledo
Hospital Universitario de la Ribera, Alzira
Hospital Clínico Universitario de Zaragoza, Zaragoza
Hospital Universitario Son Espases, Palma de Mallorca
Hospital Clínic de Barcelona, Barcelona
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Spanish Oncology Genito-Urinary Group
OTHER